Michael Rosen is a Nephrology physician. ClinicalTrials.gov lists 15 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
400 E Main St
Mount Kisco, NY 105493417
Telephone
914-241-1050Registry record last updated 15 Jun 2016.
Clinical trials
- Cytokine Response to Abdominal Wall Reconstruction
Sponsor: Northwestern University
- Tension in Posterior Component Separation for Abdominal Wall Reconstruction
Sponsor: Michael Rosen
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Travere Therapeutics, Inc.Program year20251 payment
- Novo Nordisk IncProgram year20242 payments
- GlaxoSmithKline, LLC.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
50.3%Statin24.9%Rosuvastatin Calcium48%Atorvastatin Calcium38%Simvastatin10%Pitavastatin Calcium4%Part D<11 patientsCholesterol absorption inhibitor9.6%Ezetimibe100%Part D≥42 patients+ 7 more classes in this area
Metabolism & gastrointestinal
15.8%Biguanide (metformin)3.6%Metformin Hcl74%Metformin Hcl Er27%Part D<11 patientsGLP-1 receptor agonist3.3%Mounjaro76%Ozempic24%Part D<11 patients+ 5 more classes in this area
Nervous system
13.5%SSRI4.5%Escitalopram Oxalate41%Trazodone Hcl33%Sertraline Hcl26%Part D<11 patientsBenzodiazepine2.7%Alprazolam64%Lorazepam36%Part D<11 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
10 NIH research awards on record, funded 1985–2011 per NIH RePORTER. The latest:
- Novel ion channel approaches to reentrant arrythymias
Columbia University Health Sciences
FY2011$749,107R01HL094410 - Mechanistic Determinants of Pacing-induced Cardiac Memory
Columbia University Health Sciences
FY2010$781,945R01HL067101 - Novel ion channel approaches to reentrant arrythymias
Columbia University Health Sciences
FY2010$756,673R01HL094410
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”